What is the anticipated cost of BioNexus's VitaGuard blood test, and where is it initially being commercialized?

BioNexus anticipates the cost per VitaGuard test to be under US$300, and it is progressing with commercialization of the VitaGuard™ molecular residual disease (MRD) liquid-biopsy platform in Southeast Asia, targeting an initial rollout in select medical hubs in 2026.

What recent international activities has BioNexus undertaken to support VitaGuard's commercialization?

BioNexus conducted a working visit to Tongshu Gene facilities and hospitals in China, where VitaGuard is already in paid commercial use, and has included technical planning and regulatory preparations in Malaysia and Singapore.

BioNexus Says VitaGuard Blood Tests Could Cost Under $300

Jul 28, 2026

BioNexus Gene Lab Corp plans to commercialize its VitaGuard MRD liquid-biopsy platform in Southeast Asia by 2026, with test costs projected under $300. The rollout follows successful paid use in China and targets regulatory preparations in Malaysia and Singapore.

Stock Titan

2026-02-23

BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

2026-03-12

BioNexus Gene Lab Corp. Appoints Dr. Muthu Meyyappan as CCO of Fidelion Diagnostics to Lead VitaGuard™ MRD Commercialization

2026-04-04

BioNexus Gene Lab Corp Stock Drops 3% on Poor Ratings

2026-04-14

BioNexus Gene Lab 10-K: Revenue $7.42M, EPS $(1.61)

2026-05-15

BioNexus Gene Lab Corp Q1 2026 Earnings: Revenue $22.84K, EPS ($0.23)